Iclaprim, a new selective dihydrofolate inhibitor was synthesized based on rational drug design. Iclaprim's interaction with a resistant Staphylococcus aureus dihydrofolate reductase (DHFR) is outlined in comparison to trimethoprim (TMP). This compound is active against methicillin, TMP and vancomycin resistant strains. Arpida Ltd. is developing Iclaprim for serious hospital infections from Gram-positive pathogens and respiratory tract infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2003.07.023 | DOI Listing |
Publication Analysis
Top Keywords
iclaprim novel
4
novel diaminopyrimidine
4
diaminopyrimidine potent
4
potent activity
4
activity trimethoprim
4
trimethoprim sensitive
4
sensitive resistant
4
resistant bacteria
4
bacteria iclaprim
4
iclaprim selective
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!